[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100369230":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":20,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Columbia University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CTCL group","EXPERIMENTAL","Patients with CTCL being treated with mechlorethamine gel will receive StrataCTX® gel.",[13],"Device: StrataCTX® gel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","StrataCTX® gel","Gel forming flexible wound dressing for the prevention and treatment of radiation dermatitis",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Larisa J. Geskin, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Larisa Geskin, MD","CONTACT","212-305-5293","ljg2145@cumc.columbia.edu",[32],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Columbia University Irving Medical Center","RECRUITING","New York","10032","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-74.00597,40.71427,{"lat":43,"lon":42},[46,47],{"name":27,"role":28,"phone":20,"phoneExt":20,"email":30},{"name":48,"role":24,"phone":20,"phoneExt":20,"email":20},"Larisa J Geskin, MD",{"type":24,"investigatorFullName":27,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator","100369230","stratactx-as-a-steroid-sparing-device-100369230",false,"NCT04087629","StrataCTX® as a Steroid Sparing Device","Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use as a Steroid Sparing Agent","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Ability to sign informed consent document\n* Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel\n* Patients with a diagnosis of CTCL who have intractable pruritis\n* Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief\n* Patients on chemo\u002Fimmunotherapy with drug induced rash\n\nExclusion Criteria:\n\n* Patients currently undergoing radiotherapy\n* Patients currently receiving oral steroids\n* Patients who are unable to apply topical medications","ALL","18 Years",{"count":61,"type":62},70,"ESTIMATED","INTERVENTIONAL",[65],"NA","The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy\u002Fimmunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy\u002Fimmunotherapy for solid\u002Fhematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy\u002Fimmunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.",[68],"CTCL",[68,70,71,72,73],"topical steroids","StrataCTX®","cutaneous","steroid sparing","2025-09-29",{"date":76,"type":77},"2025-10-02","ACTUAL",{"date":79,"type":77},"2021-07-07",{"date":81,"type":62},"2026-08",{"name":5,"class":6},1]